Display options
Cite
Adamek A, Kasprzak A, Seraszek A, et al. Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C. Contemp Oncol (Pozn). 2012;16(3):234-9doi: 10.5114/wo.2012.29291.
Adamek, A., Kasprzak, A., Seraszek, A., Mikoś, H., Bura, A., & Mozer-Lisewska, I. (2012). Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C. Contemporary oncology (Poznan, Poland), 16(3), 234-9. https://doi.org/10.5114/wo.2012.29291
Adamek, Agnieszka, et al. "Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C." Contemporary oncology (Poznan, Poland) vol. 16,3 (2012): 234-9. doi: https://doi.org/10.5114/wo.2012.29291
Adamek A, Kasprzak A, Seraszek A, Mikoś H, Bura A, Mozer-Lisewska I. Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C. Contemp Oncol (Pozn). 2012;16(3):234-9. doi: 10.5114/wo.2012.29291. Epub 2012 Jul 06. PMID: 23788886; PMCID: PMC3687405.
Copy Download .nbib Format: NLM
Share it on

Contemp Oncol (Pozn). 2012;16(3):234-9. doi: 10.5114/wo.2012.29291. Epub 2012 Jul 06.

Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C.

Contemporary oncology (Poznan, Poland)

Agnieszka Adamek, Aldona Kasprzak, Agnieszka Seraszek, Hanna Mikoś, Aleksandra Bura, Iwona Mozer-Lisewska

Affiliations

  1. Department of Infectious Diseases, Poznan University of Medical Sciences, Poznan, Poland.

PMID: 23788886 PMCID: PMC3687405 DOI: 10.5114/wo.2012.29291

Abstract

AIM OF THE STUDY: Deregulation of insulin-like growth factor I (IGF-I) production and decreased hepatic estrogen levels were associated with development of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) infected cirrhotic patients. The aim of our study was to determine serum levels of IGF-I, insulin and 17-β estradiol (17-βE) in relation to other markers of liver injury in chronic hepatitis C (CHC) patients.

MATERIAL AND METHODS: Thirty anti-viral treatment-naïve CHC patients and 10 healthy subjects were examined. HCV infection was confirmed by presence of anti-HCV and HCV-RNA in serum. Serum levels of IGF-I, insulin and of 17-βE were evaluated using ELISA methods.

RESULTS: Serum levels of IGF-I and 17-βE were significantly lower in CHC patients than in controls while insulin levels were similar in both groups. A lower IGF-I level (but not the level of 17-βE) was observed in cirrhotic CHC patients in comparison to non-cirrhotic ones. Decreased serum level of IGF-I was associated with more advanced staging and liver steatosis, higher levels of alpha-fetoprotein (AFP) and gamma globulin levels, and higher aspartate transaminase (AST) activity in CHC patients. Insulin and 17-βE levels positively correlated with patient's age. A positive correlation was observed between insulin level on one hand and staging, liver steatosis and levels of gamma globulins in CHC patients on the other. A negative correlation between IGF-I and insulin levels was noted only in HCV infected patients.

CONCLUSIONS: Decreased IGF-I levels and increased levels of insulin better than estradiol serum levels characterize staging and liver steatosis in CHC patients. The lower serum level of 17-βE in the CHC group than in control patients suggests that CHC patients carry higher risk of liver injury and of HCC development.

Keywords: IGF-I; estradiol; hepatitis C; insulin; liver cirrhosis

References

  1. Mol Cell Endocrinol. 1994 May;101(1-2):R1-14 - PubMed
  2. Endocrinology. 2006 Dec;147(12):5826-34 - PubMed
  3. J Clin Endocrinol Metab. 2000 May;85(5):1918-22 - PubMed
  4. Turk J Gastroenterol. 2007 Dec;18(4):245-9 - PubMed
  5. World J Gastroenterol. 2010 May 14;16(18):2265-71 - PubMed
  6. Transl Res. 2011 Sep;158(3):155-62 - PubMed
  7. Microbiol Immunol. 2010 Nov;54(11):684-90 - PubMed
  8. J Lab Clin Med. 1988 Nov;112(5):589-94 - PubMed
  9. Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):407-20 - PubMed
  10. Am J Pathol. 1999 Jan;154(1):153-67 - PubMed
  11. Liver Int. 2003 Feb;23(1):63-9 - PubMed
  12. Folia Histochem Cytobiol. 2009 Jan;47(3):385-94 - PubMed
  13. Dig Dis Sci. 2007 Nov;52(11):3245-50 - PubMed
  14. Nat Rev Cancer. 2008 Dec;8(12):915-28 - PubMed
  15. Endocr Rev. 2007 Feb;28(1):20-47 - PubMed
  16. Hepatogastroenterology. 2003 May-Jun;50(51):814-6 - PubMed
  17. Scand J Gastroenterol. 2000 Nov;35(11):1212-5 - PubMed
  18. Biochem Pharmacol. 2004 Sep 15;68(6):1003-15 - PubMed
  19. Clin Chim Acta. 2000 Apr;294(1-2):169-77 - PubMed
  20. Cancer. 2002 Dec 15;95(12):2539-45 - PubMed
  21. J Clin Lab Anal. 2010;24(3):195-200 - PubMed
  22. Diabetes Care. 2006 May;29(5):1096-101 - PubMed
  23. Int J Cancer. 2000 Jul 1;87(1):118-21 - PubMed
  24. World J Gastroenterol. 2004 Sep 15;10(18):2740-3 - PubMed
  25. Clin Sci Mol Med. 1974 Oct;47(4):359-66 - PubMed
  26. Endocr Rev. 1989 Feb;10(1):68-91 - PubMed

Publication Types